Anti-inflammatory diet for people with lupus
Official title: Effect of Anti-inflammatory Diet in Systemic Lupus Erythematous
Run by University of California, San Diego · NCT07713940 · Data updated 2026-11-12
This study tests whether an anti-inflammatory diet can affect symptoms and biological markers in people with systemic lupus erythematosus who are already taking Cellcept or Mycophenolate.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 36 (estimated) |
| Sponsor | University of California, San Diego Academic / other |
| Locations | 1 site (La Jolla, California) |
| Status | Recruiting |
| Started | July 1, 2026 |
| Main results expected | July 1, 2028 |
| Study ends | July 1, 2029 |
| Registry record updated | November 6, 2026 |
| Trial ID | NCT07713940 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with SLE who are on Cellcept or Mycophenolate for at least 3 months and report pain interference on PROMIS, as per inclusion criteria.
✕Probably not a fit
Patients who do not respond to dietary changes or whose disease activity is driven by factors other than inflammation may see no benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
In this exploratory, short-term study, researchers will have participants follow an anti-inflammatory diet and will compare blood and stool samples collected before and after the dietary change to identify inflammatory markers and gut bacteria linked to disease activity. The goal is to generate preliminary data on how diet may influence lupus biology and potential mechanisms behind flares. No placebo or pharmacologic intervention is tested, and the study emphasizes biomarkers and microbiome changes alongside clinical signs. Findings could inform future strategies for managing lupus through diet and personalized approaches.
Why it matters
Potential benefit: If successful, the diet could help reduce inflammation and potentially influence disease activity or flare risk in lupus patients.
How similar studies have gone: Previous research in autoimmune diseases suggests diet can modulate inflammation and gut microbiota, but specific results for lupus and anti-inflammatory diets are still preliminary.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients who meet the 2019 EULAR/ACR Classification Criteria for SLE * patients who are on Cellcept or Myfortic for at least 3 months prior to screening * patients with a score of ≥55 on the Patient Reported Outcomes Measurement Information System (PROMIS) Pain interference scale. Exclusion Criteria: * pregnant or lactating patients, * patients with food allergy * patients on antibiotics within 4 weeks of the screening * patients that change the SLE therapy during the length of the study (12 weeks).
Where it's running
-
Altman Clinical Translational Research Insitute (UC San Diego)
La Jolla, California, United States Recruiting
Study contacts
- Principal investigator: Monica Guma, MD, PhD — UC San Diego
- Study coordinator: Monica Guma, MD, PhD
- Email: mguma@health.ucsd.edu
- Phone: 858-822-6523
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CD19/BCMA UCART for B cell–related autoimmune diseases
This early-stage study tests QT-219CX, a universal allogeneic CAR-T cell therapy that targets CD19 and BCMA, in people with refractory B-cell–related autoimmune diseases to see if it can be given safely and provide early signs of benefit.
-
Allogeneic CD19/BCMA CAR‑T for B‑cell autoimmune disease
This Phase 1 study will test a donor-derived CAR‑T therapy that targets CD19 and BCMA to try to reset the immune system in people with refractory B‑cell autoimmune diseases such as SLE, IgA nephropathy, systemic sclerosis, and resistant nephrotic syndrome.
-
HB2198 for adults with moderate to severe lupus, including lupus nephritis and extra‑renal lupus
This trial will test whether two intravenous doses of HB2198 can safely reduce B cells and improve disease measures in adults with moderate to severe lupus, including lupus nephritis and extra‑renal lupus.
-
Allogeneic CAR T cells targeting CD19 and BCMA for B‑cell autoimmune diseases
This study will try a single infusion of off‑the‑shelf CAR T cells that target CD19 and BCMA to treat people with B‑cell–mediated autoimmune diseases such as lupus, IgA nephropathy, and drug‑resistant nephrotic syndrome.
-
Reducing unnecessary medications in older adults with rheumatic conditions
This project will test whether giving doctors individualized MedSafer reports plus patient EMPOWER brochures helps people 60+ with rheumatic conditions who take five or more regular medications stop or reduce risky medicines.
-
2-HOBA for Lupus: A 2-period crossover study to see if scavenging IsoLGs lowers blood pressure
This phase II study tests whether 2-HOBA taken three times daily can reduce blood pressure and immune activation in adults with systemic lupus erythematosus compared to placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.